Actinogen Reveals Promising Data on Alzheimer’s Therapy at AAIC 2016, Readies Phase 2 Trial

Actinogen Reveals Promising Data on Alzheimer’s Therapy at AAIC 2016, Readies Phase 2 Trial
Actinogen Medical announced early clinical study data for Xanamem, a drug designed to lower brain cortisol and intended for the treatment of Alzheimer’s disease, at the Alzheimer’s Association International Conference (AAIC) 2016, held in Toronto, Canada. Xanamem works by blocking excess cortisol production in the hippocampus and frontal cortex, two brain areas that are particularly affected by Alzheimer’s. The concept is based on findings showing that chronic stress and elevated cortisol levels lead to changes in the brain that affect memory, the development of amyloid plaques, and the death of neurons. The development of Xanamem is also supported by recent data, presented at the AAIC, demonstrating that increased levels of the stress hormone cortisol in the blood increases the likelihood of developing Alzheimer’s. The findings were part of the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) — an ambitious program with the goal to identify factors, both biological and environmental, that impact the development of Alzheimer’s. The study, “Plasma cortisol, amyloid-β and cognitive decline in preclinical Alzheimer’s disease,” which enrolled 416 people, also found that cortisol seems to interact with amyloid-beta to speed up cognitive decline, independent of a range of risk factors, including age, education, APOE and BDNF genotype, blood vessel disease, depression, and anxiety. “We have demonstrated that when levels of cortisol, the ‘stress hormone,’
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *